Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.

J Urol · 2026 · PMC12978717 · PMID 41349040

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The key secondary end point of OS was numerically better with enzalutamide monotherapy vs leuprolide alone, although differences did not reach statistical significance, and the data had not reached maturity at the time of interim analysis.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.